NCT07002203 — Seqker Biosciences neoantigen vaccine trial
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Registry record
| Registry ID | NCT07002203 ↗ |
|---|---|
| Lead sponsor | Seqker Biosciences, Inc. |
| Collaborators | Bumrungrad International Hospital |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Indication | Solid Tumors, Advanced Cancer, Recurrent Cancer, Neoantigen-Specific Immunotherapy, Personalized Cancer Vaccine |
| Enrollment | 10 participants (target) |
| Start date | 2024-03-01 |
| Primary completion | 2027-08 (est.) |
| Last registry update | 24 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07002203), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07002203?
NCT07002203 (Personalized Neoantigen Peptide Vaccines for Solid Tumors) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by Seqker Biosciences, Inc..
Is NCT07002203 recruiting?
As of the 2026-07-24 registry update, NCT07002203 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07002203?
The lead sponsor is Seqker Biosciences, Inc.. Collaborators: Bumrungrad International Hospital.
What condition does NCT07002203 study?
The registered conditions are Solid Tumors, Advanced Cancer, Recurrent Cancer, Neoantigen-Specific Immunotherapy, Personalized Cancer Vaccine. Primary completion is listed as 2027-08 (estimated).
Are results available for NCT07002203?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07002203.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.